Lazertinib (Lazcluze) 80/240mg | Janssen US Originator | GLT

Generic Information: Lazcluze (United States)

Lazcluze is the United States brand of lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor held by Janssen Biotech, a Johnson & Johnson company. Lazertinib was discovered in South Korea and out-licensed to Janssen, which developed it into the first chemotherapy-free combination regimen proven superior to osimertinib in first-line EGFR-mutated lung cancer. The American presentation is supplied as film-coated tablets in two strengths, 80 mg and 240 mg, both taken by mouth.

What Is Lazertinib (Lazcluze) Used For?

Lazcluze is indicated, together with amivantamab, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumours carry EGFR exon 19 deletions or exon 21 L858R substitution mutations. Regimens that pair lazertinib with amivantamab target two cancer drivers at once — the intracellular EGFR kinase and the extracellular EGFR/MET signalling axis — and are chosen by oncologists based on confirmatory mutation testing.

How Does Lazertinib Work?

Lazertinib belongs to the newest class of EGFR blockers. Inside the tumour cell it binds irreversibly to the ATP pocket of mutated EGFR, shutting down the growth signals that drive squamous-free adenocarcinoma proliferation, while largely sparing normal EGFR in skin and gut tissue. That mutant selectivity explains both its efficacy and its comparatively tolerable profile, and because the molecule reaches the central nervous system well, it offers meaningful protection against brain metastases, a common failure site in lung cancer.

Indications

The regulatory approval covers first-line use with amivantamab in EGFR exon 19 deletion or L858R mutation-positive locally advanced or metastatic NSCLC, detected by an approved test. In routine practice, eligibility is confirmed by molecular pathology, performance status is assessed before starting, and the combination continues until disease progression or unacceptable toxicity. Patients with brain metastases are eligible and represent an important group for this regimen.

Dosage

The recommended dose is 240 mg taken orally once daily, with or without food, swallowed whole with water — tablets must not be chewed, split or crushed. A 240 mg daily dose can be taken as one 240 mg tablet or as three 80 mg tablets. When started together with amivantamab, the antibody follows a split first dose and then moves to weekly or less frequent infusion, while the daily tablet continues unchanged. If a dose is missed and more than twelve hours remain before the next one, take it as soon as remembered.

Side Effects

In the pivotal combination trial, frequently reported effects included rash, paronychia (nail-fold inflammation), musculoskeletal pain, fatigue, mouth sores, constipation, decreased appetite, itching, diarrhoea and low thyroid hormone. Because the partner antibody amivantamab is given by infusion, infusion-related reactions and venous blood clots are specific risks of the regimen, and inflammation of the lungs (interstitial lung disease or pneumonitis) requires immediate medical attention. Regular monitoring of skin, nails, thyroid function and magnesium levels is standard care.

Storage

Lazcluze tablets are an oral solid supplied in bottles and stored at controlled room temperature, protected from moisture and heat — no refrigeration is needed. Blister and bottle packaging travels safely by ambient express courier. GLT ships from a Hong Kong-licensed facility with full batch documentation enclosed.

Why Choose Lazcluze Through GLT?

Overseas patients and institutions sourcing the American originator through GLT gain access to Janssen Biotech's FDA-approved Lazcluze with verified cold-secure, ambient-condition logistics, batch traceability and documentation suitable for hospital pharmacy review. For buyers weighing the originator against regional alternatives, GLT also supplies the China and Korea originator presentations as well as the Laos generic, allowing a like-for-like comparison under one supplier.

How to Order

To order Lazcluze (lazertinib) from GLT, message us on WhatsApp at +86 15234153837 or write to [email protected]. Our team confirms current stock, quantity pricing and delivery timelines to your country, and dispatches from a Hong Kong-licensed facility.

FAQ

Is Lazcluze the same drug as Leclaza? Yes. Leclaza (South Korea) and Lazcluze (United States) are the same lazertinib molecule marketed by Yuhan and Janssen respectively under different brand names.

How does the Lazcluze combination compare with osimertinib? In the phase 3 MARIPOSA study, first-line lazertinib plus amivantamab extended median progression-free survival to 23.7 months versus 16.6 months for osimertinib, roughly a 30 percent reduction in the risk of progression or death.

Can Lazcluze be taken alone? The American label covers use together with amivantamab; monotherapy decisions rest with the treating oncologist.